Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention
- 1 May 2010
- journal article
- review article
- Published by Elsevier BV in Rheumatic Disease Clinics of North America
- Vol. 36 (2), 385-404
- https://doi.org/10.1016/j.rdc.2010.03.003
Abstract
No abstract availableKeywords
This publication has 135 references indexed in Scilit:
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnnals Of The Rheumatic Diseases, 2009
- Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialAnnals Of The Rheumatic Diseases, 2008
- Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD studyAnnals Of The Rheumatic Diseases, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumabAnnals Of The Rheumatic Diseases, 2007
- Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineagesNature Immunology, 2005
- Canonical Wnt Signaling in Differentiated Osteoblasts Controls Osteoclast DifferentiationDevelopmental Cell, 2005
- IL-1α affects mineralized nodule formation by rat osteoblastsLife Sciences, 2004
- IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesisJCI Insight, 1999